Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Personalized Adjuvant Treatment for HR+/HER2- breast cancer FOR YOUNG patients

Project description

Assays for personalised breast cancer treatment

Approximately 7 million women are living with or beyond breast cancer, with 25 % of breast cancer cases in the EU occurring in premenopausal women. These women face burdensome treatments such as chemotherapy. While gene-expression assays can help identify postmenopausal patients who can avoid chemotherapy, studies focusing on high-risk premenopausal women treated with optimal endocrine therapy are lacking. The EU-funded PATH-FOR-YOUNG project aims to evaluate the role of specific assays to guide treatment for 5 000 patients, building on an ongoing twin randomised controlled trial. The project will also explore digital self-management tools to support patients, particularly during endocrine therapy, improving quality of life. A comprehensive health technology assessment will help facilitate cross-country implementation.

Objective

Worldwide, ~7 million women live with or beyond Breast Cancer (BC), as 10-year survival rates exceeding 80% for early-stage (I-III) BC. Premenopausal BC accounts for 25% in the EU and 55% in low/middle income countries. Most premenopausal women with BC have high risk of recurrence, therefore standard treatment includes adjuvant chemo- (CT) and endocrine therapy (ET). However, treatment has substantial physical, emotional and social burden, which is often more pressing for younger compared to older patients.
Gene-expression assays are used for post-menopausal patients to identify women who can safely forego CT without detriment on clinical outcomes, preserving Quality of Life (QOL). However, a definitive study has yet to be conducted among premenopausal women with high-risk HR+HER2-BC. The primary objective of PATH-FOR-YOUNG is to conduct a pragmatic randomized controlled trial (RCT) with 5000 patients validating the use of a gene-expression assay to drive adjuvant treatment decisions in this target population.
PATH-FOR-YOUNG aims to achieve its objective in 7 years. The project (i) builds on and complements an ongoing twin RCT to ensure timely recruitment, (ii) leverages on a large international consortium of oncologists, pathologists, patient representatives, psychologists, sociologists, ethics and communication experts, biostatisticians, health economists, and technology providers, to assure complementary and multidisciplinary expertise, and (iii) highlights patient-engagement, participatory care, and early involvement of end users. PATH-FOR-YOUNG will also study implementation of digital self-management to support patients throughout the cancer journey and particularly while on ET to improve QOL and medication adherence. A full HTA will ensure a path towards cross-country implementation.
PATH-FOR-YOUNG has the ambition to improve BC care, fully integrating the predictive, personalized, preventive, and participatory principles of health management.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2024-DISEASE-03-two-stage

See all projects funded under this call

Coordinator

UNICANCER
Net EU contribution
€ 4 447 320,40
Address
101 RUE DE TOLBIAC
75013 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Participants (22)

Partners (4)